Hopefully I'm not getting all excited over nothing, however, it looks like these folks:
www.cebix.com are going to be starting trials in early 2010 and hopefully coming to market not too long after that.
C-peptide is one of those things that I have been dying to see somebody develop and bring to market for as long as I have been aware of it.In a healthy body, insulin isn’t produced alone, it is produced as pro-insulin which is a combination of insulin + C-peptide.If my limited understanding of this is accurate, insulin is somewhat damaging by nature and the C-peptide is the natural mitigating factor to some of that damage.
Dr. Brownlee believes he has found a unified mechanism for the complications brought on by diabetes and he thinks he has a way of interrupting that chemical process and preventing the complications. I have the Banting award lecture he gave and the journal article of the human trial on my home page here on Juvenation (lower right corner 01 & 02...)
Hi A-D, this might be off topic but maybe you can help me. I contacted Dr. Brownlee after your post of those articles concerning the Diabetologia release and never got a reply. The figures on page 2 show significant differences between control and diabetic participants at Week 0. What wasn't clear to me was whether the diabetic levels at Weeks 2 and 4 were signficantly different from diabetic levels at Week 0. control levels at Week 0, or both values at Week 0. I was also wondering if there was any info about Weeks 2 and 4 being significantly different from each other.
To my (highly untrained eye) eye, each of the three graphs represent a separate series of chemical measurements.Each starts with a week 0 comparison between non-diabetic and diabetic levels.In all three graphs at week 0, each of the levels are dramatically different between diabetics and non-diabetics.Following the trail out to the second and fourth weeks it appears to me that it is showing the following:
·Angiopoietin-2 levels in serum of non-diabetic and type 1 diabetic participants the non-diabetic level appears to be around 1500, whereas the diabetic range is just under 2500 at week 0
oAt weeks two and four the diabetic range drops to around 1000 and yes, this is an appreciabledifference from the week 0 level of 2500
·Intracellular N-acetylglucosamine-modified protein (GlcNAc) in monocytes from non-diabetic and type 1 diabetic participants before and during treatment at week zero the non-diabetic level is a little over 1000 where the diabetic level is at nearly 4000
oAt week two the diabetic level appears to drop to nearly 2500 and at week four it appears to be about 2000
·6-keto-PGF1α levels in serum of non-diabetic and type 1 diabetic participants before and during same treatment seem to show the non-diabetic group in week 0 at about 5500 while the diabetic group is at about 1500.
oAt week two the diabetic level raises to around 4000 and by week four is nearly 5000.
The underlying assumption is that the non-diabetic levels for these substances remain constant throughout.I expect this is true but I do not know if they have the data to show it.
Given the way I’m reading it, I am not completely sure I am clear about your questions or if my reviewing what I saw and how I read it helped or hindered.This may be better suited to an email/phone call if you want to spend a few minutes seeing what we can figure out together… hehehe